| Type | Title | Date Released | |
|---|---|---|---|
8-K | Shuttle Pharmaceuticals Holdings, Inc. Engages New Independent Registered Public Accounting Firm | ||
8-K | Shuttle Pharmaceuticals Holdings, Inc. Dismisses Independent Accounting Firm Forvis Mazars, LLP | ||
10-Q | Form 10-Q | ||
8-K/A | Amendment clarifies that 9,741,751 pre-funded warrants were actually issued as of September 9, 2026, not the previously reported maximum. | ||
8-K | Shuttle Pharmaceuticals Holdings, Inc. Announces Unregistered Sales of Equity Securities Following Stockholder Approval | ||
8-K | Shuttle Pharmaceuticals Holdings, Inc. Announces Results of Special Meeting of Stockholders | ||
DEFA14A | Form DEFA14A | ||
8-K | Shuttle Pharmaceuticals Holdings, Inc. Postpones Special Meeting of Stockholders | ||
8-K | Shuttle Pharmaceuticals Holdings, Inc. Amends Merger Agreement Milestone Event | ||
8-K | Shuttle Pharmaceuticals Receives NASDAQ Noncompliance Notice Regarding Delayed Form 10-Q | ||
NT 10-Q | Form NT 10-Q | ||
8-K/A | Merger with United Dogecoin Inc. deemed not significant; financial statements and pro forma information not required. |
